{"url_path":"/sec/lgnd/8-k/2026-06-25/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/886163/0001193125-26-282990-index.html","accession_number":"0001193125-26-282990","cik":"0000886163","ticker":"LGND","issuer_name":"LIGAND PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/886163/0001193125-26-282990-index.html","primary_entity_key":"0000886163","primary_entity_name":"LIGAND PHARMACEUTICALS INC"},"word_count":155,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\nNo.\n\n  \n\nDescription\n\n 4.1\n  \n[Indenture, dated as of June 25, 2026, by and between Ligand Pharmaceuticals Incorporated and U.S. Bank National Association, as Trustee.](d167360dex41.htm)\n\n 4.2\n  \n[Form of Global Note, representing Ligand Pharmaceuticals Incorporated’s 0.00% Convertible Senior Notes due 2031 (included as Exhibit A to the Indenture filed as Exhibit 4.1).](d167360dex41.htm)\n\n10.1\n  \n[Form of Convertible Note Hedge Transaction Confirmation.](d167360dex101.htm)\n\n10.2\n  \n[Form of Warrant Transaction Confirmation.](d167360dex102.htm)\n\n99.1\n  \n[Press Release dated as of June 22, 2026.](d167360dex991.htm)\n\n99.2\n  \n[Press Release dated as of June 25, 2026.](d167360dex992.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nLIGAND PHARMACEUTICALS INCORPORATED\n\nDate: June 25, 2026\n \n\n \nBy:\n \n\n/s/ Andrew Reardon\n\n \n\n \nName:\n \nAndrew Reardon\n\n \n\n \nTitle:\n \nChief Legal Officer and Secretary"}